Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
36
SPRO Quote, Financials, Valuation and Earnings
Last price:
$2.34
Seasonality move
:
17.06%
Day range:
$2.31 - $2.42
52-week range:
$0.51 - $3.22
Dividend yield:
0%
P/E ratio:
10.75x
P/S ratio:
4.42x
P/B ratio:
4.95x
Volume:
245.3K
Avg. volume:
371.8K
1-year change:
152.49%
Market cap:
$131.3M
Revenue:
$27.4M
EPS (TTM):
-$0.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$0.32 | -100% | -3.03% | $4.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$780.4M | $0.34 | 11.37% | 43.52% | $89.74 |
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.08% | 236.17% | $15.25 |
|
GOVX
GeoVax Labs, Inc.
|
-- | -- | -100% | -- | $9.63 |
|
OMER
Omeros Corp.
|
-- | -$0.48 | -- | -0.15% | $28.00 |
|
SAVA
Cassava Sciences, Inc.
|
-- | -$0.68 | -- | -36% | $8.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SPRO
Spero Therapeutics, Inc.
|
$2.33 | $4.00 | $131.3M | 10.75x | $0.00 | 0% | 4.42x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$61.14 | $89.74 | $11.7B | 22.91x | $0.00 | 0% | 3.88x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.21 | $15.25 | $4.4B | -- | $0.00 | 0% | 7.27x |
|
GOVX
GeoVax Labs, Inc.
|
$0.19 | $9.63 | $5.7M | -- | $0.00 | 0% | 0.83x |
|
OMER
Omeros Corp.
|
$8.75 | $28.00 | $620.4M | -- | $0.00 | 0% | -- |
|
SAVA
Cassava Sciences, Inc.
|
$2.20 | $8.00 | $106.3M | -- | $0.00 | 0% | 2.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SPRO
Spero Therapeutics, Inc.
|
11.23% | 12.710 | 3.17% | 3.63x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.764 | 5.87% | 2.84x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
GOVX
GeoVax Labs, Inc.
|
-- | 1.075 | -- | 2.75x |
|
OMER
Omeros Corp.
|
254.22% | -1.203 | 126.5% | 0.76x |
|
SAVA
Cassava Sciences, Inc.
|
-- | 4.880 | -- | 2.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$9.7M | -97.58% | -107.04% | -319% | $17.4M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
GOVX
GeoVax Labs, Inc.
|
-$16.8K | -$6.4M | -433.69% | -433.69% | -635.8% | -$6.2M |
|
OMER
Omeros Corp.
|
-$240K | -$26.4M | -59.56% | -- | -- | -$18.5M |
|
SAVA
Cassava Sciences, Inc.
|
-$200K | -$11.9M | -86.98% | -86.98% | -- | -$6.3M |
Spero Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SPRO or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of -3.91%. Spero Therapeutics, Inc.'s return on equity of -107.04% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About SPRO or BMRN?
Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 71.67%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $89.74 which suggests that it could grow by 50.87%. Given that Spero Therapeutics, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Spero Therapeutics, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPROSpero Therapeutics, Inc.0 1 0 BMRNBioMarin Pharmaceutical, Inc.13 7 0 -
Is SPRO or BMRN More Risky?
Spero Therapeutics, Inc. has a beta of 1.482, which suggesting that the stock is 48.19% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.071%.
-
Which is a Better Dividend Stock SPRO or BMRN?
Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRO or BMRN?
Spero Therapeutics, Inc. quarterly revenues are $3M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Spero Therapeutics, Inc.'s net income of -$7.4M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while BioMarin Pharmaceutical, Inc.'s PE ratio is 22.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.42x versus 3.88x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPROSpero Therapeutics, Inc.4.42x 10.75x $3M -$7.4M BMRNBioMarin Pharmaceutical, Inc.3.88x 22.91x $786.8M -$30.7M
-
Which has Higher Returns SPRO or FOLD?
Amicus Therapeutics, Inc. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of 10.24%. Spero Therapeutics, Inc.'s return on equity of -107.04% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About SPRO or FOLD?
Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 71.67%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 7.32%. Given that Spero Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Spero Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPROSpero Therapeutics, Inc.0 1 0 FOLDAmicus Therapeutics, Inc.3 4 0 -
Is SPRO or FOLD More Risky?
Spero Therapeutics, Inc. has a beta of 1.482, which suggesting that the stock is 48.19% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock SPRO or FOLD?
Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRO or FOLD?
Spero Therapeutics, Inc. quarterly revenues are $3M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Spero Therapeutics, Inc.'s net income of -$7.4M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.42x versus 7.27x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPROSpero Therapeutics, Inc.4.42x 10.75x $3M -$7.4M FOLDAmicus Therapeutics, Inc.7.27x -- $169.1M $17.3M
-
Which has Higher Returns SPRO or GOVX?
GeoVax Labs, Inc. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of -630.04%. Spero Therapeutics, Inc.'s return on equity of -107.04% beat GeoVax Labs, Inc.'s return on equity of -433.69%.
Company Gross Margin Earnings Per Share Invested Capital SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M -
What do Analysts Say About SPRO or GOVX?
Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 71.67%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $9.63 which suggests that it could grow by 4947.2%. Given that GeoVax Labs, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Spero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPROSpero Therapeutics, Inc.0 1 0 GOVXGeoVax Labs, Inc.4 0 0 -
Is SPRO or GOVX More Risky?
Spero Therapeutics, Inc. has a beta of 1.482, which suggesting that the stock is 48.19% more volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.638, suggesting its more volatile than the S&P 500 by 263.848%.
-
Which is a Better Dividend Stock SPRO or GOVX?
Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRO or GOVX?
Spero Therapeutics, Inc. quarterly revenues are $3M, which are larger than GeoVax Labs, Inc. quarterly revenues of --. Spero Therapeutics, Inc.'s net income of -$7.4M is lower than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.42x versus 0.83x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPROSpero Therapeutics, Inc.4.42x 10.75x $3M -$7.4M GOVXGeoVax Labs, Inc.0.83x -- -- -$6.3M
-
Which has Higher Returns SPRO or OMER?
Omeros Corp. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of --. Spero Therapeutics, Inc.'s return on equity of -107.04% beat Omeros Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M OMEROmeros Corp.-- -$0.47 $143M -
What do Analysts Say About SPRO or OMER?
Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 71.67%. On the other hand Omeros Corp. has an analysts' consensus of $28.00 which suggests that it could grow by 220%. Given that Omeros Corp. has higher upside potential than Spero Therapeutics, Inc., analysts believe Omeros Corp. is more attractive than Spero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPROSpero Therapeutics, Inc.0 1 0 OMEROmeros Corp.2 2 0 -
Is SPRO or OMER More Risky?
Spero Therapeutics, Inc. has a beta of 1.482, which suggesting that the stock is 48.19% more volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.485, suggesting its more volatile than the S&P 500 by 148.518%.
-
Which is a Better Dividend Stock SPRO or OMER?
Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRO or OMER?
Spero Therapeutics, Inc. quarterly revenues are $3M, which are larger than Omeros Corp. quarterly revenues of --. Spero Therapeutics, Inc.'s net income of -$7.4M is higher than Omeros Corp.'s net income of -$21.2M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.42x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPROSpero Therapeutics, Inc.4.42x 10.75x $3M -$7.4M OMEROmeros Corp.-- -- -- -$21.2M
-
Which has Higher Returns SPRO or SAVA?
Cassava Sciences, Inc. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of --. Spero Therapeutics, Inc.'s return on equity of -107.04% beat Cassava Sciences, Inc.'s return on equity of -86.98%.
Company Gross Margin Earnings Per Share Invested Capital SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M SAVACassava Sciences, Inc.-- -$0.22 $81.6M -
What do Analysts Say About SPRO or SAVA?
Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 71.67%. On the other hand Cassava Sciences, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 263.64%. Given that Cassava Sciences, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe Cassava Sciences, Inc. is more attractive than Spero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPROSpero Therapeutics, Inc.0 1 0 SAVACassava Sciences, Inc.1 0 0 -
Is SPRO or SAVA More Risky?
Spero Therapeutics, Inc. has a beta of 1.482, which suggesting that the stock is 48.19% more volatile than S&P 500. In comparison Cassava Sciences, Inc. has a beta of -1.081, suggesting its less volatile than the S&P 500 by 208.123%.
-
Which is a Better Dividend Stock SPRO or SAVA?
Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. Cassava Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRO or SAVA?
Spero Therapeutics, Inc. quarterly revenues are $3M, which are larger than Cassava Sciences, Inc. quarterly revenues of --. Spero Therapeutics, Inc.'s net income of -$7.4M is higher than Cassava Sciences, Inc.'s net income of -$10.8M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Cassava Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.42x versus 2.69x for Cassava Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPROSpero Therapeutics, Inc.4.42x 10.75x $3M -$7.4M SAVACassava Sciences, Inc.2.69x -- -- -$10.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
